B7-H1 antibodies lose antitumor activity due to activation of p38 MAPK that leads to apoptosis of tumor-reactive CD8+T cells

Scientific Reports

Volumn 6, Issue , 2016, Pages

  Liu, Xin ^a   Wu, Xiaosheng ^a   Cao, Siyu ^a   Harrington, Susan M ^a   Yin, Peng ^a   Mansfield, Aaron S ^a   Dong, Haidong ^a,b  

^a MAYO CLINIC   (United States)

^b MAYO GRADUATE SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; CD274 PROTEIN, MOUSE; MITOGEN ACTIVATED PROTEIN KINASE P38; PROGRAMMED DEATH 1 LIGAND 1;

ANIMAL; APOPTOSIS; BAGG ALBINO MOUSE; C57BL MOUSE; CD8+ T LYMPHOCYTE; CELL SURVIVAL; CYTOLOGY; CYTOPLASM; ENZYME ACTIVATION; EXPERIMENTAL MELANOMA; GENE DELETION; IMMUNOTHERAPY; KNOCKOUT MOUSE; LYMPHOCYTE ACTIVATION; MAPK SIGNALING; METABOLISM; MOUSE; PHENOTYPE; TUMOR CELL LINE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; B7-H1 ANTIGEN; CD8-POSITIVE T-LYMPHOCYTES; CELL LINE, TUMOR; CELL SURVIVAL; CYTOPLASM; ENZYME ACTIVATION; GENE DELETION; IMMUNOTHERAPY; LYMPHOCYTE ACTIVATION; MAP KINASE SIGNALING SYSTEM; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; MICE, KNOCKOUT; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHENOTYPE;

EID: 84994476884     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep36722     Document Type: Article

References (26)

1. Dong, H. et al. Tumor-associated B7-H1 promotes T-cell apoptosis: a potential mechanism of immune evasion. Nat. Med. 8, 793-800, doi: 10.1038/nm730nm730 [pii] (2002).
2. Iwai, Y. et al. Involvement of PD-L1 on tumor cells in the escape from host immune system and tumor immunotherapy by PD-L1 blockade. Proc. Natl. Acad. Sci. U S A 99, 12293-12297, doi: 10.1073/pnas.192461099 (2002).
3. Topalian, S. L., Drake, C. G. & Pardoll, D. M. Targeting the PD-1/B7-H1(PD-L1) pathway to activate anti-tumor immunity. Curr. Opin. Immunol. 24, 207-212, doi: 10.1016/j.coi.2011.12.009 (2012).
4. Brahmer, J. R. et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N. Engl. J. Med. 366, 2455-2465, doi: 10.1056/NEJMoa1200694 (2012).
5. Powles, T. et al. MPDL3280A (anti-PD-L1) treatment leads to clinical activity in metastatic bladder cancer. Nature 515, 558-562, doi: 10.1038/nature13904 (2014).
6. Herbst, R. S. et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature 515, 563-567, doi: 10.1038/nature14011 (2014).
7. Xu, D. et al. A Potential New Pathway for PD-L1 Costimulation of the CD8-T Cell Response to Listeria monocytogenes Infection. PloS one 8, e56539, doi: 10.1371/journal.pone.0056539 (2013).
8. Rowe, J. H., Johanns, T. M., Ertelt, J. M. & Way, S. S. PDL-1 blockade impedes T cell expansion and protective immunity primed by attenuated Listeria monocytogenes. J. Immunol. 180, 7553-7557, doi: 180/11/7553 [pii] (2008).
9. Dong, H. et al. Costimulating aberrant T cell responses by B7-H1 autoantibodies in rheumatoid arthritis. J. Clin. Invest. 111, 363-370, doi: 10.1172/JCI16015 (2003).
10. Liu, X. et al. Endogenous tumor-reactive CD8 T cells are differentiated effector cells expressing high levels of CD11a and PD-1 but are unable to control tumor growth. Oncoimmunology 2, e23972, doi: 10.4161/onci.23972 (2013).
11. + tumor-reactive repertoire infiltrating human tumors. J. Clin. Invest. 124, 2246-2259, doi: 10.1172/JCI73639 (2014).
12. Joshi, N. S. et al. Inflammation directs memory precursor and short-lived effector CD8(+) T cell fates via the graded expression of T-bet transcription factor. Immunity 27, 281-295, doi: 10.1016/j.immuni.2007.07.010 (2007).
13. Pulko, V. et al. B7-h1 expressed by activated CD8 T cells is essential for their survival. J. Immunol. 187, 5606-5614, doi: 10.4049/jimmunol.1003976 (2011).
14. Park, J. J. et al. B7-H1/CD80 interaction is required for the induction and maintenance of peripheral T-cell tolerance. Blood 116, 1291-1298, doi: blood-2010-01-265975 [pii] 10.1182/blood-2010-01-265975 (2010).
15. Butte, M. J., Keir, M. E., Phamduy, T. B., Sharpe, A. H. & Freeman, G. J. Programmed death-1 ligand 1 interacts specifically with the B7-1 costimulatory molecule to inhibit T cell responses. Immunity 27, 111-122, doi: S1074-7613(07)00328-7 [pii] 10.1016/j. immuni.2007.05.016 (2007).
16. Merritt, C. et al. Activation of p38 mitogen-activated protein kinase in vivo selectively induces apoptosis of CD8(+) but not CD4(+) T cells. Mol. Cell. Biol. 20, 936-946 (2000).
17. + T cells. Mol. Cell. Biol. 26, 2118-2129, doi: 10.1128/MCB.26.6.2118-2129.2006 (2006).
18. Hirano, F. et al. Blockade of B7-H1 and PD-1 by monoclonal antibodies potentiates cancer therapeutic immunity. Cancer Res. 65, 1089-1096, doi: 65/3/1089 [pii] (2005).
19. Ueha, S. et al. Robust Antitumor Effects of Combined Anti-CD4-Depleting Antibody and Anti-PD-1/PD-L1 Immune Checkpoint Antibody Treatment in Mice. Cancer immunology research 3, 631-640, doi: 10.1158/2326-6066.CIR-14-0190 (2015).
20. Frigola, X. et al. Soluble B7-H1: differences in production between dendritic cells and T cells. Immunology letters 142, 78-82, doi: 10.1016/j.imlet.2011.11.001 (2012).
21. Shao, L. et al. Deficiency of the DNA repair enzyme ATM in rheumatoid arthritis. J. Exp. Med. 206, 1435-1449, doi: 10.1084/jem.20082251 (2009).
22. Shao, L., Goronzy, J. J. & Weyand, C. M. DNA-dependent protein kinase catalytic subunit mediates T-cell loss in rheumatoid arthritis. EMBO molecular medicine 2, 415-427, doi: 10.1002/emmm.201000096 (2010).
23. Panta, G. R. et al. ATM and the catalytic subunit of DNA-dependent protein kinase activate NF-kappaB through a common MEK/extracellular signal-regulated kinase/p90(rsk) signaling pathway in response to distinct forms of DNA damage. Mol. Cell. Biol. 24, 1823-1835 (2004).
24. Yotsumoto, S., Saegusa, K. & Aramaki, Y. Endosomal translocation of CpG-oligodeoxynucleotides inhibits DNA-PKcs-dependent IL-10 production in macrophages. J Immunol. 180, 809-816 (2008).
25. Koul, H. K., Pal, M. & Koul, S. Role of p38 MAP Kinase Signal Transduction in Solid Tumors. Genes Cancer 4, 342-359, doi: 10.1177/1947601913507951 (2013).
26. Saha, A. et al. Programmed death ligand-1 expression on donor T cells drives graft-versus-host disease lethality. J. Clin. Invest. 126, 2642-2660, doi: 10.1172/JCI85796 (2016).